PL3400025T3 - Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu - Google Patents

Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu

Info

Publication number
PL3400025T3
PL3400025T3 PL17736394.2T PL17736394T PL3400025T3 PL 3400025 T3 PL3400025 T3 PL 3400025T3 PL 17736394 T PL17736394 T PL 17736394T PL 3400025 T3 PL3400025 T3 PL 3400025T3
Authority
PL
Poland
Prior art keywords
guaiacol
prevention
treatment
storage disease
glycogen storage
Prior art date
Application number
PL17736394.2T
Other languages
English (en)
Inventor
Hasan Orhan AKMAN
Salvatore Dimauro
Or KAKHLON
Weil Miguel
Original Assignee
The Trustees Of Columbia University In The City Of New York
Hadasit Medical Research Services And Development Ltd.
Ramot At Tel-Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York, Hadasit Medical Research Services And Development Ltd., Ramot At Tel-Aviv University Ltd. filed Critical The Trustees Of Columbia University In The City Of New York
Publication of PL3400025T3 publication Critical patent/PL3400025T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0362Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/48Reserve carbohydrates, e.g. glycogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL17736394.2T 2016-01-06 2017-01-06 Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu PL3400025T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275471P 2016-01-06 2016-01-06
PCT/US2017/012455 WO2017120420A1 (en) 2016-01-06 2017-01-06 The use of guaiacol for the prevention and treatment of glycogen storage disease

Publications (1)

Publication Number Publication Date
PL3400025T3 true PL3400025T3 (pl) 2024-06-24

Family

ID=59274197

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17736394.2T PL3400025T3 (pl) 2016-01-06 2017-01-06 Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu

Country Status (7)

Country Link
US (1) US10933031B2 (pl)
EP (1) EP3400025B1 (pl)
ES (1) ES2979171T3 (pl)
HU (1) HUE066497T2 (pl)
IL (1) IL260450B (pl)
PL (1) PL3400025T3 (pl)
WO (1) WO2017120420A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11712432B2 (en) * 2018-12-20 2023-08-01 University Of Kentucky Research Foundation Method of treating cancer with an elevated glycogen content
WO2021183554A1 (en) * 2020-03-09 2021-09-16 University Of Kentucky Research Foundation Manipulating glycogen in alzheimer's disease, epilepsy, traumatic brain injury, and als as a treatment
CN120919090B (zh) * 2025-10-16 2025-12-23 山东第一医科大学附属省立医院(山东省立医院) 愈创木酚或其衍生物在制备预防或治疗代谢综合征药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199695A (ja) 1992-03-06 1994-07-19 Yunie:Kk 糖尿病改善治療剤
GB0308952D0 (en) * 2003-04-17 2003-05-28 St Georges Entpr Ltd Method
WO2005044247A1 (en) 2003-11-07 2005-05-19 Oaky Natural Co., Ltd Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar
EP2132309A4 (en) * 2007-02-23 2011-01-05 Univ Florida COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
US8679478B2 (en) * 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
WO2016090001A1 (en) 2014-12-02 2016-06-09 The Trustees Of Columbia University In The City Of New York Deep intronic mutation found adult polyglucosan body disease and uses thereof
WO2016161086A1 (en) * 2015-03-31 2016-10-06 Duke University Methods and compositions for treating glycogen storage diseases using agents that mimic or elevate cyclic amp

Also Published As

Publication number Publication date
IL260450B (en) 2022-06-01
US20190015355A1 (en) 2019-01-17
EP3400025A4 (en) 2019-12-11
EP3400025B1 (en) 2024-03-13
EP3400025C0 (en) 2024-03-13
HUE066497T2 (hu) 2024-08-28
ES2979171T3 (es) 2024-09-24
EP3400025A1 (en) 2018-11-14
US10933031B2 (en) 2021-03-02
WO2017120420A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
IL273550A (en) Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the I148M variant of PNPLA3
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL258810A (en) Materials and methods for treating glycogen storage disease type 1a
IL269096A (en) Treatment of glycogen storage disease 3
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL266047A (en) Methods and preparations for the treatment of Fabry disease
IL246579A0 (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
IL290955A (en) Compounds for the treatment of glycogen storage diseases
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL280570A (en) Mini-GDE for the treatment of glycogen storage disease III
ES2856150T5 (en) Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases
SMT202300260T1 (it) Composti a base di indolinoni e loro utilizzo nel trattamento di patologie fibrotiche
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
PL3400025T3 (pl) Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL261834A (en) Cd31shed agonists for use in the prevention and/or treatment of reperfusion injury
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases
PL3166660T3 (pl) Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
IL251407B (en) A multivalent compound for the treatment and prevention of brain damage